Praxis Precision Medicines, Inc. (PRAX)

NASDAQ: PRAX · Real-Time Price · USD
36.52
+0.86 (2.40%)
Apr 2, 2025, 2:47 PM EDT - Market open
2.40%
Market Cap 736.36M
Revenue (ttm) 8.55M
Net Income (ttm) -182.82M
Shares Out 20.16M
EPS (ttm) -10.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open 35.14
Previous Close 35.87
Day's Range 35.00 - 37.91
52-Week Range 30.01 - 91.83
Beta 2.65
Analysts Strong Buy
Price Target 123.33 (+237.71%)
Earnings Date May 12, 2025

About PRAX

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The company offers cerebrum, a small molecule platform for CNS small molecule therapies and solidus, an antisense oligonucleotide platform to discover and develop antisense oligonucleotide. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of es... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 16, 2020
Employees 116
Stock Exchange NASDAQ
Ticker Symbol PRAX
Full Company Profile

Financial Performance

In 2024, PRAX's revenue was $8.55 million, an increase of 249.53% compared to the previous year's $2.45 million. Losses were -$182.82 million, 48.3% more than in 2023.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for PRAX stock is "Strong Buy." The 12-month stock price forecast is $123.33, which is an increase of 237.71% from the latest price.

Price Target
$123.33
(237.71% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies fo...

4 weeks ago - GlobeNewsWire

Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade)

Ulixacaltamide's Phase 3 study was recommended to stop for futility, significantly lowering its chances of success in essential tremor. Investor focus shifts to the epilepsy pipeline, led by vormatrig...

4 weeks ago - Seeking Alpha

Praxis Precision Medicines Provides Update on Essential3 and Corporate Update

BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...

4 weeks ago - GlobeNewsWire

Praxis Precision Medicines to Present at Two February Investor Conferences

BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies fo...

2 months ago - GlobeNewsWire

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025; anticipate four commercial assets by 2028

2 months ago - GlobeNewsWire

Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome

Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those ...

3 months ago - GlobeNewsWire

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx today announced Biogen, Praxis Precision Medicines and Stoke Therapeutics as the founding partners to its Patient Access Program for epilepsy.

Other symbols: BIIBSTOKWGS
4 months ago - Business Wire

Praxis Precision Medicines to Present at Upcoming December Investor Conferences

BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies fo...

4 months ago - GlobeNewsWire

Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences

BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...

5 months ago - GlobeNewsWire

Praxis Precision Medicines, Inc. (PRAX) Q3 2024 Earnings Call Transcript

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Q3 2024 Earnings Conference Call November 6, 2024 8:00 AM ET Company Participants Dan Ferry - IR, LifeSci Communications Marcio Souza - President & CEO ...

5 months ago - Seeking Alpha

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing anticipated in 2025

5 months ago - GlobeNewsWire

Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024

BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies fo...

5 months ago - GlobeNewsWire

Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations

BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies fo...

7 months ago - GlobeNewsWire

Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine

Placebo-adjusted monthly motor seizure reduction of 46% during double-blind period Over 30% of patients achieved seizure freedom status while on relutrigine Meaningful gains observed in alertness, com...

7 months ago - GlobeNewsWire

Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024

BOSTON, Mass., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ther...

7 months ago - GlobeNewsWire

These Analysts Increase Their Forecasts On Praxis Precision Medicines After Q2 Results

Praxis Precision Medicines, Inc. PRAX reported a loss for the second quarter on Tuesday.

8 months ago - Benzinga

Praxis Precision Medicines, Inc. (PRAX) Q2 2024 Earnings and Corporate Update Call Transcript

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Q2 2024 Earnings Conference Call August 13, 2024 8:00 AM ET Company Participants Marcio Souza - President and Chief Executive Officer Tim Kelly - Chief ...

8 months ago - Seeking Alpha

Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024

BOSTON, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...

8 months ago - GlobeNewsWire

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

BOSTON, May 17, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...

11 months ago - GlobeNewsWire

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results

Plans to initiate two efficacy studies investigating PRAX-628 in focal onset seizures in the second half of 2024 and first half of 2025, respectively

11 months ago - GlobeNewsWire

Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024

BOSTON, May 10, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...

11 months ago - GlobeNewsWire

Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting

Innovative design of ongoing Phase 3 clinical program expected to set precedent for future clinical trials in essential tremor Innovative design of ongoing Phase 3 clinical program expected to set pre...

1 year ago - GlobeNewsWire

Praxis Precision Medicines to Participate in Upcoming April Conferences

BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies fo...

1 year ago - GlobeNewsWire

Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering

BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies fo...

1 year ago - GlobeNewsWire

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies fo...

1 year ago - GlobeNewsWire